Alpha Cognition (ACOGD) | Financial Analysis & Statements
Alpha Cognition Inc. Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2024Income Metrics
Revenue
0
Operating Income
-2.4M
Net Income
-1.9M
EPS (Diluted)
$-0.31
Balance Sheet Metrics
Total Assets
5.0M
Total Liabilities
7.9M
Shareholders Equity
-2.9M
Cash Flow Metrics
Operating Cash Flow
-1.3M
Free Cash Flow
-1.6M
Revenue & Profitability Trend
Alpha Cognition Income Statement From 2023 to 2023
| Metric | 2023 |
|---|---|
| Revenue | 0 |
| Cost of Goods Sold | - |
| Gross Profit | - |
| Gross Margin % | 0.0% |
| Operating Expenses | |
| Research & Development | 5.0M |
| Selling, General & Administrative | 4.7M |
| Other Operating Expenses | -154.2K |
| Total Operating Expenses | 9.5M |
| Operating Income | -9.6M |
| Operating Margin % | 0.0% |
| Non-Operating Items | |
| Interest Income | 6.8K |
| Interest Expense | 67.7K |
| Other Non-Operating Income | -4.1M |
| Pre-tax Income | -13.8M |
| Income Tax | - |
| Effective Tax Rate % | 0.0% |
| Net Income | -13.8M |
| Net Margin % | 0.0% |
| Key Metrics | |
| EBITDA | -9.5M |
| EPS (Basic) | $-3.75 |
| EPS (Diluted) | $-3.75 |
| Basic Shares Outstanding | 3774219 |
| Diluted Shares Outstanding | 3774219 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Alpha Cognition Balance Sheet From 2023 to 2023
| Metric | 2023 |
|---|---|
| Assets | |
| Current Assets | |
| Cash & Equivalents | 1.4M |
| Short-term Investments | - |
| Accounts Receivable | - |
| Inventory | - |
| Other Current Assets | 366.3K |
| Total Current Assets | 1.9M |
| Non-Current Assets | |
| Property, Plant & Equipment | 1.7K |
| Goodwill | 532.0K |
| Intangible Assets | 532.0K |
| Long-term Investments | - |
| Other Non-Current Assets | - |
| Total Non-Current Assets | 533.7K |
| Total Assets | 2.5M |
| Liabilities | |
| Current Liabilities | |
| Accounts Payable | 475.6K |
| Short-term Debt | 1.2M |
| Current Portion of Long-term Debt | - |
| Other Current Liabilities | - |
| Total Current Liabilities | 2.6M |
| Non-Current Liabilities | |
| Long-term Debt | - |
| Deferred Tax Liabilities | - |
| Other Non-Current Liabilities | 84.1K |
| Total Non-Current Liabilities | 4.5M |
| Total Liabilities | 7.2M |
| Equity | |
| Common Stock | 50.4M |
| Retained Earnings | -63.4M |
| Treasury Stock | - |
| Other Equity | - |
| Total Shareholders Equity | -4.7M |
| Key Metrics | |
| Total Debt | 1.2M |
| Working Capital | -706.5K |
Balance Sheet Composition
Alpha Cognition Cash Flow Statement From 2023 to 2023
| Metric | 2023 |
|---|---|
| Operating Activities | |
| Net Income | -13.8M |
| Depreciation & Amortization | 84.5K |
| Stock-Based Compensation | 2.4M |
| Working Capital Changes | 0 |
| Operating Cash Flow | -11.3M |
| Investing Activities | |
| Capital Expenditures | 0 |
| Acquisitions | - |
| Investment Purchases | - |
| Investment Sales | - |
| Investing Cash Flow | 0 |
| Financing Activities | |
| Share Repurchases | - |
| Dividends Paid | 0 |
| Debt Issuance | - |
| Debt Repayment | -55.0K |
| Financing Cash Flow | 8.2M |
| Free Cash Flow | -8.7M |
| Net Change in Cash | -3.1M |
Cash Flow Trend
Alpha Cognition Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.75
Forward P/E
11.45
Price to Book
-13.53
PEG Ratio
11.45
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
292.25%
Return on Assets
-374.07%
Financial Health
Current Ratio
0.96
Debt to Equity
-0.41
Beta
3.29
Per Share Data
EPS (TTM)
$-3.75
Book Value per Share
$-0.23
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ACOGD | 37.0M | -1.75 | -13.53 | 292.25% | 0.00% | -0.41 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Alnylam | 41.9B | 132.73 | 52.09 | 73.28% | 8.45% | 376.19 |
| Royalty Pharma plc | 29.4B | 27.89 | 3.29 | 13.20% | 32.42% | 92.33 |
| Insmed | 31.0B | -22.40 | 40.88 | -249.28% | -210.54% | 101.43 |
Financial data is updated regularly. All figures are in the company's reporting currency.